https://www.biopharmawatch.com/news/BETR/betterlife-pharma-us100-million-public-offering BiopharmaWatch en 2026-09-11T23:45:00.000Z BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants https://www.biopharmawatch.com/news/MRBK/meridian-corporation-fiduciary-duties-investigation BiopharmaWatch en 2026-09-11T22:48:00.000Z SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Meridian Corporation (NASDAQ: MRBK). https://www.biopharmawatch.com/news/SRRK/fda-approval-isembyld-apitegromab-sma BiopharmaWatch en 2026-09-11T22:25:00.000Z Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) https://www.biopharmawatch.com/news/ENBI.X/entheon-adopts-semi-annual-reporting BiopharmaWatch en 2026-09-11T22:18:00.000Z Entheon Adopts Semi-Annual Reporting https://www.biopharmawatch.com/news/CLLS/cellectis-conference-call-business-update-september-2026 BiopharmaWatch en 2026-09-11T20:30:00.000Z Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update https://www.biopharmawatch.com/news/CMPS/strata-mental-health-solutions-training-grant-comp360 BiopharmaWatch en 2026-09-11T20:10:00.000Z Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360 https://www.biopharmawatch.com/news/AGMB/agomab-appointments-marino-garcia-naimish-patel BiopharmaWatch en 2026-09-11T20:05:10.000Z Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors https://www.biopharmawatch.com/news/IBO/impact-biomedical-reverse-stock-split-merger-zoar-ltd BiopharmaWatch en 2026-09-11T20:05:00.000Z Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.) https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-canyon-1-trial-data BiopharmaWatch en 2026-09-11T20:01:00.000Z Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity https://www.biopharmawatch.com/news/PHAR/fda-approves-pharming-joenja-treatment-apds-children BiopharmaWatch en 2026-09-11T18:00:00.000Z FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S. https://www.biopharmawatch.com/news/ACVA/acv-auctions-investigation-copart-sale BiopharmaWatch en 2026-09-11T17:00:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ACV Auctions Inc. (NYSE: ACVA) https://www.biopharmawatch.com/news/AHCO/adapthealth-participate-investor-conferences BiopharmaWatch en 2026-09-11T17:00:00.000Z AdaptHealth To Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-shares-august-2026 BiopharmaWatch en 2026-09-11T16:30:00.000Z Sanofi: Information concerning the total number of voting rights and shares - August 2026 https://www.biopharmawatch.com/news/ARAY/accuray-raysearch-collaboration-online-adaptive-therapy BiopharmaWatch en 2026-09-11T15:28:00.000Z Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities https://www.biopharmawatch.com/news/LLY/lilly-acquires-ataibeckley-mental-health-therapies BiopharmaWatch en 2026-09-11T13:02:00.000Z Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-11T13:00:45.000Z Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/WAT/waters-corporation-jp-morgan-all-stars-conference BiopharmaWatch en 2026-09-11T13:00:00.000Z Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference https://www.biopharmawatch.com/news/PHGE/tessera-begins-trading-hlsq-demand-connected-security BiopharmaWatch en 2026-09-11T12:30:00.000Z Tessera Begins Trading Under HLSQ as Demand Grows for Connected Physical Security https://www.biopharmawatch.com/news/MBRX/moleculin-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-11T12:30:00.000Z Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-nasdaq-qntm-filling-key-gap-ms-treatment BiopharmaWatch en 2026-09-11T12:30:00.000Z Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-private-placement BiopharmaWatch en 2026-09-11T12:00:34.000Z Tempest Therapeutics Announces Up to $7.5 Million Private Placement https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-11-5-million-financing BiopharmaWatch en 2026-09-11T12:00:00.000Z Glucotrack Announces $11.5 Million Financing https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-effectiveness-1-80-reverse-stock-split BiopharmaWatch en 2026-09-11T12:00:00.000Z Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split https://www.biopharmawatch.com/news/IMMP/immutep-focused-development-strategy-efti BiopharmaWatch en 2026-09-11T12:00:00.000Z Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”) https://www.biopharmawatch.com/news/CMND/clearmind-enrolls-first-patients-aud-cmnd-100-trial BiopharmaWatch en 2026-09-11T12:00:00.000Z Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-spac-registration-filing BiopharmaWatch en 2026-09-11T12:00:00.000Z Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement https://www.biopharmawatch.com/news/GTBP/gt-biopharma-host-live-presentation-trike-platform BiopharmaWatch en 2026-09-11T12:00:00.000Z GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026 https://www.biopharmawatch.com/news/ELAN/elanco-third-quarter-2026-financial-results BiopharmaWatch en 2026-09-11T11:58:00.000Z Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement https://www.biopharmawatch.com/news/ELOX/eloxx-phase-2b-exact-study-exaluren BiopharmaWatch en 2026-09-11T11:30:00.000Z Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome https://www.biopharmawatch.com/news/COSM/cosmos-health-secures-viofar-contract-manufacturing BiopharmaWatch en 2026-09-11T11:10:00.000Z Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-11T11:01:00.000Z Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fireside-chat-hc-wainwright-conference BiopharmaWatch en 2026-09-11T11:00:00.000Z Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-zeta-tms-robotic-system BiopharmaWatch en 2026-09-11T11:00:00.000Z NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System https://www.biopharmawatch.com/news/DARE/dare-bioscience-hc-wainwright-conference-presentation BiopharmaWatch en 2026-09-11T10:55:00.000Z Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand https://www.biopharmawatch.com/news/BLCO/bausch-lomb-ce-mark-approval-seelyra-laser BiopharmaWatch en 2026-09-11T10:11:00.000Z Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-first-half-2026-results BiopharmaWatch en 2026-09-11T09:00:00.000Z Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/NVNO/envveno-medical-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-11T07:00:00.000Z enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand https://www.biopharmawatch.com/news/ECIA/encision-completes-private-placement-funding BiopharmaWatch en 2026-09-11T05:00:00.000Z Encision Completes $80,000 Private Placement https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-pricing-public-offering BiopharmaWatch en 2026-09-11T01:11:00.000Z Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering https://www.biopharmawatch.com/news/NUTX/nutex-health-cybersecurity-update BiopharmaWatch en 2026-09-10T23:00:00.000Z NUTEX HEALTH PROVIDES UPDATE REGARDING CYBERSECURITY EVENT https://www.biopharmawatch.com/news/EW/edwards-lifesciences-tavr-coverage-decision BiopharmaWatch en 2026-09-10T21:49:00.000Z Edwards Lifesciences Comments on TAVR National Coverage Decision https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-files-shelf-prospectus BiopharmaWatch en 2026-09-10T21:00:00.000Z Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ce-marking-acuvue-oasys-max BiopharmaWatch en 2026-09-10T20:35:00.000Z Johnson & Johnson reçoit le marquage CE pour les lentilles de contact réutilisables ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/jnj-ce-marking-acuvue-oasys-max-contact-lenses BiopharmaWatch en 2026-09-10T20:35:00.000Z Johnson & Johnson erhält CE-Kennzeichnung für wiederverwendbare Kontaktlinsen der Marke ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/resumen-johnson-amp-johnson-obtiene-el-marcado-ce-para-las BiopharmaWatch en 2026-09-10T20:35:00.000Z Resumen: Johnson & Johnson obtiene el marcado CE para las lentillas reutilizables ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ce-mark-acuvue-oasys-max BiopharmaWatch en 2026-09-10T20:35:00.000Z Riassunto: Johnson & Johnson riceve il marchio CE per le lenti a contatto riutilizzabili ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/ce-marking-johnson-johnson-acuvue-oasys-max BiopharmaWatch en 2026-09-10T20:35:00.000Z Samenvatting: Johnson & Johnson ontvangt CE-markering voor herbruikbare ACUVUE OASYS MAX-contactlenzen https://www.biopharmawatch.com/news/PSYC/psyched-wellness-secured-term-loan BiopharmaWatch en 2026-09-10T20:15:00.000Z Psyched Wellness Announces Secured Term Loan https://www.biopharmawatch.com/news/DXCM/dexcom-appoints-glenn-boehnlein-board-directors BiopharmaWatch en 2026-09-10T20:15:00.000Z Dexcom Appoints Glenn Boehnlein to Board of Directors https://www.biopharmawatch.com/news/A/agilent-participate-jp-morgan-all-stars-conference BiopharmaWatch en 2026-09-10T20:15:00.000Z Agilent to Participate in J.P. Morgan U.S. All Stars Conference https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-10T20:15:00.000Z Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-leadership-transition BiopharmaWatch en 2026-09-10T20:10:00.000Z TransCode Therapeutics Announces Leadership Transition https://www.biopharmawatch.com/news/SI/shoulder-innovations-fda-clearance-n22-humeral-head-launch BiopharmaWatch en 2026-09-10T20:05:00.000Z Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch https://www.biopharmawatch.com/news/TMDX/transmedics-appoints-fernando-araujo-cfo-2026-outlook BiopharmaWatch en 2026-09-10T20:05:00.000Z TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-appoints-vijay-iyengar-board BiopharmaWatch en 2026-09-10T20:05:00.000Z Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-lyl273-manufacturing-transfer-update BiopharmaWatch en 2026-09-10T20:05:00.000Z Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/SER/serina-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T20:05:00.000Z Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ELUT/elutia-presents-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-10T20:05:00.000Z Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-public-offering BiopharmaWatch en 2026-09-10T20:03:00.000Z Yarrow Bioscience Announces Proposed Underwritten Public Offering https://www.biopharmawatch.com/news/SEPN/septerna-inc-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-09-10T20:00:00.000Z Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-virtual-investor-day-september-2026 BiopharmaWatch en 2026-09-10T20:00:00.000Z Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026